UBS initiated coverage of ALX Oncology (ALXO) with a Buy rating and $6 price target The company has a potential blockbuster program with a CD47 combo currently in Phase II for metastatic breast cancer, the analyst tells investors in a research note. UBS sees ALX reporting a “robust” dataset in mid-2027, demonstrating CD47 inhibitor evorpacept’s efficacy in CD47 high and/or HER2+ metastatic breast cancer patients.

Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions

Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on ALXO:

Disclaimer & DisclosureReport an Issue

ALX Oncology reports Q4 EPS (42c), consensus (36c)

ALXO Earnings this Week: How Will it Perform?

ALX Oncology price target raised to $4 from $3 at Piper Sandler

ALX Oncology announces major underwritten public equity offering

ALX Oncology Highlights Biomarker Data and Cash Position